Dual GIPR/GLP1R co-agonists were shown to be safe and efficacious in humans (16), and recently tirzepatide was the first GIPR/GLP1R co-agonist to receive regulatory approval for the treatment T2DM in 2022. Here, GLP1R is linked to type 2 diabetes mellitus.